U
BSTG

UBS’s Biostage, Inc. Common Stock BSTG Stock Holding History

UBS’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
887
-1,588
-64% -$13K ﹤0.01% 9217
2014
Q2 		$26K Buy
2,475
+1,875
+313% +$16K ﹤0.01% 7758
2014
Q1 		$5K Sell
600
-2,096
-78% -$12.4K ﹤0.01% 9601
2013
Q4 		$13K Buy
+2,696
New +$12.6K ﹤0.01% 8734

Other funds holding BSTG

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS's BSTG Position: Q3 2014 in Review

UBS reduced its Biostage, Inc. Common Stock (BSTG) stake by 64% in Q3 2014, selling an estimated $13K and leaving 887 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #9217.

UBS first reported a position in BSTG in Q4 2013 and has held it in 4 quarters since. The position peaked at $26K in Q2 2014. 43 funds tracked by Wall St. Rank hold BSTG as of Q3 2014.

  • UBS held 887 shares of Biostage, Inc. Common Stock worth $7K as of Q3 2014.
  • UBS sold 1,588 Biostage, Inc. Common Stock shares in Q3 2014, an estimated $13K.
  • Biostage, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9217 holding.
  • UBS first reported a position in Biostage, Inc. Common Stock in Q4 2013 and has held it in 4 quarters since.
  • UBS's Biostage, Inc. Common Stock position peaked at $26K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.